《2024 年度内部控制自我评价报告》客观、真实地反映 了公司内部控制体系的建设及运行情况。监事会一致同意公 司《2024 年度内部控制自我评价报告》。 广东嘉应制药股份有限公司 监事会对公司 2024 年度内部控制评价报告的意见 根据《公司法》《深圳证券交易所上市公司自律监管指 引第 1 号 ——主板上市公司规范运作》等法律法规的要求， 结合广东嘉应制药股份有限公司（以下简称"公司"）董事 会对公司截至 2024 年 12 月 31 日（内部控制评价报告基准 日）的内部控制有效性进行了评价。公司监事会认真审阅了 公司《2024 年度内部控制自我评价报告》，现发表核查意见 如下： 公司内部控制发现并披露了公司存在关联方非经营性 资金往来和关联方财务资助的情况，截止 2025年 1月 23日， 资金已全部被归还，包括本金及利息。同时，公司还存在关 联方披露不准确不完整、关联交易未经审议且未披露等情况。 上述事项说明公司资金管理和信息披露上存在内部控制缺 陷，在资金事后控制活动中未明确并及时跟踪检查资金等事 项。 上述内控问题发现后，公司采取一系列措施及时整改， 包括更换董事会秘书、设立内控专员岗强化内部控制管控 ...

第七届监事会第二次会议决议公告 证券代码：002198 证券简称：嘉应制药 公告编号：2025-021 广东嘉应制药股份有限公司 第七届监事会第二次会议决议公告 本公司及全体监事会成员保证本公告内容的真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 1、广东嘉应制药股份有限公司（以下简称"公司"）第七届监事会第二次 会议通知已于 2025 年 4 月 14 日分别以专人送达、电子邮件或传真等方式送达公 司全体监事。2025 年 4 月 24 日会议如期以现场结合视频和邮件通讯方式举行。 2、会议应到监事3名，实到监事3名。 3、经全体与会人员举手同意，会议由监事钟高华先生主持。 4、会议的召集、召开符合法律、法规及公司章程的规定，表决形成的决议 合法、有效。 二、监事会会议审议情况 会议以投票表决方式通过了以下议案： 1、会议以3票同意，0票反对，0票弃权审议通过了《关于公司<2024年年度 报告>及<2024年年度报告摘要>的议案》。 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上披露的《2024 年年 度报告》，以及在《证券时报》、《中国证券报》、 ...

第七届董事会第二次会议决议公告 证券代码：002198 证券简称：嘉应制药 公告编号：2025-020 广东嘉应制药股份有限公司 第七届董事会第二次会议决议公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 1、会议以 9 票同意，0票反对，0票弃权审议通过了《关于公司<2024年年 度报告>及<2024年年度报告摘要>的议案》； 具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上披露的《2024 年年 度报告》，以及在《证券时报》、《中国证券报》、《证券日报》和巨潮资讯网 （www.cninfo.com.cn）上披露的《2024 年年度报告摘要》。 第七届董事会第二次会议决议公告 公司审计委员会、监事会分别对《关于公司<2024 年年度报告>及<2024 年年 度报告摘要>的议案》发表了同意意见，本议案尚需提交股东大会审议。 1、广东嘉应制药股份有限公司（以下简称"公司"） 第七届董事会第二次 会议通知已于 2025 年 4 月 14 日以专人送达、电子邮件和电话等方式送达全体董 事、监事及高级管理人员。2025 ...

本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 特别提示： 关于 2024 年度拟不进行利润分配的公告 证券代码：002198 证券简称：嘉应制药 公告编号：2025-022 广东嘉应制药股份有限公司 关于 2024 年度拟不进行利润分配的公告 1.截至 2024 年 12 月 31 日，公司合并报表未分配利润为 99,290,524.82 元，母公司未分配利润为 16,346,842.23 元。公司2024年度利润分配预案为：不 派发现金红利，不送红股，不以资本公积转增股本。 2.公司利润分配预案不涉及《深圳证券交易所股票上市规则》第 9.8.1条相关 规定的可能被实施其他风险警示情形。 一、审议程序 广东嘉应制药股份有限公司 (以下简称"公司")于 2025 年 4 月 24 日 召开了第七届董事会第二次会议及第七届监事会第二次会议，审议通过了《关 于公司<2024 年度利润分配预案>的议案》，公司董事会、监事会均认为本次利 润分配预案符合《公司法》等法律法规、《公司章程》及《公司未来三年（2024-2026 年）股东回报规划》关于利润分配的相关规定，综 ...

| 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 东方证券股份有限公司 | 5214.80 | 10.28 | 不变 | | 养天和大药房股份有限公司 | 3552.57 | 7.00 | 不变 | | 黄俊杰 | 2550.51 | 5.03 | 不变 | | 广东嘉应创业投资基金管理有限公司 | 1600.31 | 3.15 | -54.30 | | 陈少彬 | 1525.28 | 3.01 | 不变 | | 林少贤 | 1150.02 | 2.27 | 不变 | | 王庆新 | 561.88 | 1.11 | 不变 | | 李胜喜 | 498.00 | 0.98 | 21.60 | | 黄锐伟 | 480.00 | 0.95 | 不变 | | 中信证券资产管理(香港)有限公司-客户资金 | 407.56 | 0.80 | -82.87 | | 较上个报告期退出前十大股东有 | | | | 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 ...

Financial Performance - The company's operating revenue for 2024 was ¥376,167,156.57, a decrease of 29.46% compared to ¥533,233,202.29 in 2023[19] - The net profit attributable to shareholders for 2024 was ¥20,611,599.55, down 39.94% from ¥34,320,234.64 in 2023[19] - The net profit after deducting non-recurring gains and losses was ¥14,552,294.96, a decline of 52.82% from ¥30,845,270.89 in 2023[19] - The net cash flow from operating activities was ¥60,848,965.10, which is a 38.20% decrease from ¥98,453,750.09 in 2023[19] - Basic earnings per share for 2024 were ¥0.0406, down 39.94% from ¥0.0676 in 2023[19] - Total assets at the end of 2024 were ¥838,820,451.71, a slight decrease of 1.03% from ¥847,563,113.21 at the end of 2023[19] - The net assets attributable to shareholders at the end of 2024 were ¥758,220,755.10, down 0.62% from ¥762,984,647.95 at the end of 2023[19] - The weighted average return on equity for 2024 was 2.71%, down from 4.60% in 2023[19] Dividend and Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares[5] - The company has established a cash dividend policy that requires at least 10% of the distributable profit to be allocated as cash dividends annually[186] - The company will not distribute cash dividends or issue bonus shares this year, opting to retain profits for future funding needs[188] - The employee stock ownership plan includes 64 core employees holding a total of 13,500,000 shares, representing 2.66% of the company's total equity[190] Market and Product Development - The company is focused on enhancing the quality of traditional Chinese medicine and promoting high-quality industry development through technological innovation[34] - The company has a total of over 70 approved drug products across 5 dosage forms, focusing on areas such as throat, cold, orthopedics, rheumatology, gynecology, liver and gallbladder, tonics, and gastrointestinal medicine[41] - The company launched new products including the solid essence ginseng pill and the large packaging of the strong waist and kidney pill, with the former exceeding sales expectations in the first quarter[59] - The company is focusing on the development of the Jiegusuan product line to enhance market share and innovation[82] - The company aims to optimize its product structure and enhance quality control, focusing on product innovation and clinical value to improve market value[40] Research and Development - The company is committed to increasing research and development investment, with a focus on innovative projects such as the development of bone-setting products and gynecological treatments[48] - R&D investment amounted to ¥6,757,234.58 in 2024, down 33.09% from ¥10,098,497.62 in 2023[84] - The company's R&D personnel decreased from 42 in 2023 to 30 in 2024, a reduction of 28.57%[84] - The company is increasing R&D investment, aiming to enhance the proportion of R&D expenses and promote the secondary development of "Gujin Canrong Wan"[116] Governance and Compliance - The company has established a comprehensive governance framework, including a clear division of responsibilities among the shareholders' meeting, board of directors, and management team[124] - The company operates independently without a controlling shareholder, maintaining complete separation in business, personnel, assets, and financial aspects[129] - The company has established a comprehensive investor relations management system to facilitate effective communication with investors[128] - The company emphasizes the protection of minority shareholders' rights through equitable treatment in shareholder meetings[128] - The company has no direct or indirect interference from major shareholders in its operational decisions[129] Operational Efficiency and Cost Control - The company has implemented cost control measures and improved production efficiency through automation upgrades, significantly reducing production costs[55] - The company operates under a sales-driven production model, where production plans are based on annual sales forecasts and market conditions, ensuring compliance with GMP standards[45] - The company is focusing on optimizing production management and expanding capacity through the construction of new production lines and modern smart production equipment[108] Strategic Acquisitions and Partnerships - The company completed the acquisition of a 7% stake by Yangtianhe, becoming the second-largest shareholder, which is expected to enhance resource allocation and collaboration[63] - The company's main sales strategy involves establishing partnerships with medical institutions and participating in centralized procurement processes across various provinces[46] Internal Control and Audit - The internal control audit report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024[196] - The internal control audit report was disclosed on April 26, 2025, with a clean opinion that included an emphasis of matter[196] - The company has implemented corrective measures to address internal control issues, including appointing a new board secretary and enhancing internal control management[191] Employee Management and Compensation - The total compensation for directors, supervisors, and senior management in 2024 amounted to 2.6015 million yuan[162] - The company has established a personnel management system as the basis for determining the compensation of senior management[161] - The company's salary policy includes a structure of basic salary, position salary, performance salary, allowances/subsidies, and benefits, closely linked to company performance and individual work performance[178] Future Outlook - The company has provided a revenue guidance for the next fiscal year, projecting an increase of 8% to 10%[143] - New product launches are expected to contribute an additional 1.5 billion in revenue over the next two years[141] - The company aims to improve operational efficiency by 15% through new automation technologies[142] - The company is actively seeking opportunities for market expansion and potential acquisitions to strengthen its competitive position[145]

Revenue and Profitability - The company's revenue for Q1 2025 was ¥121,632,944.06, representing a year-over-year increase of 28.83% compared to ¥94,415,395.08 in the same period last year[5] - Net profit attributable to shareholders increased by 197.23% to ¥15,403,257.18 from ¥5,182,187.84 year-over-year[5] - The net profit after deducting non-recurring gains and losses surged by 315.11% to ¥15,751,018.59 from ¥3,794,433.53 in the previous year[5] - Basic earnings per share rose by 198.04% to ¥0.0304 from ¥0.0102 year-over-year[5] - Net profit for the current period was ¥15,403,257.18, representing a significant increase of 196.5% compared to ¥5,182,187.84 in the previous period[18] - Operating profit rose to ¥19,327,230.54, compared to ¥6,255,016.14, marking a 208.5% increase[18] - The total comprehensive income for the current period was ¥15,403,257.18, compared to ¥5,182,187.84 in the previous period, indicating strong growth[18] Assets and Liabilities - The company's total assets decreased by 3.12% to ¥812,635,918.09 from ¥838,820,451.71 at the end of the previous year[5] - Total assets decreased to ¥812,635,918.09 from ¥838,820,451.71, reflecting a reduction of approximately 3.1%[16] - Total liabilities increased to ¥88,487,902.21 from ¥80,599,696.61, indicating an increase of about 9.4%[15] - The company's total equity decreased to ¥724,148,015.88 from ¥758,220,755.10, a decline of approximately 4.5%[16] Cash Flow and Operating Activities - Cash flow from operating activities turned negative at -¥11,833,754.83, a decline of 193.73% compared to ¥12,624,935.63 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥11,833,754.83, a decline from a net inflow of ¥12,624,935.63 in the previous period[19] - Cash and cash equivalents at the end of the period totaled ¥264,960,176.44, compared to ¥117,068,956.84 at the end of the previous period[20] - The company's cash and cash equivalents decreased to ¥264,960,176.44 from ¥336,141,154.38, representing a decline of approximately 21.2%[14] Accounts Receivable and Payable - Accounts receivable increased by ¥54,579,600, a growth of 70.89%, primarily due to revenue growth[11] - Accounts receivable increased significantly to ¥131,571,107.23 from ¥76,991,474.27, marking an increase of about 71.2%[14] - The company reported a significant increase in accounts payable, which rose to ¥11,606,617.68 from ¥12,607,576.55, a decrease of about 7.9%[15] Expenses - The company reported a significant increase in sales expenses, which rose by 33.84% to ¥4,417,000, attributed to revenue growth[11] - The company experienced a significant increase in sales expenses, which rose to ¥44,206,430.98 from ¥33,029,036.77, an increase of 33.9%[17] - Total operating costs amounted to ¥101,544,275.20, up from ¥89,135,396.31, reflecting a 13.5% increase[17] - Research and development expenses decreased to ¥1,699,113.63 from ¥2,031,024.37, a reduction of 16.3%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,345, with the largest shareholder holding 10.28% of the shares[10] Product Development and Market Activity - The company has not reported any new product developments or market expansions during this period[12] - There are no indications of mergers or acquisitions in the recent financial disclosures[12]

本着审慎原则及对广大投资者负责的态度，同时为确保定期报告披露内容的 真实性、准确性和完整性，公司决定将《2024 年年度报告》及《2025 年第一季 度报告》的披露时间调整至 2025 年 4 月 26 日。 目前公司生产经营一切正常。公司董事会对本次调整定期报告披露时间而给 投资者带来的不便深表歉意，敬请广大投资者谅解。巨潮资讯网、《证券时报》、 《中国证券报》、《证券日报》为公司信息披露的指定报纸及网站，公司所有信息 均以在上述媒体披露的信息为准，敬请投资者理性投资，注意风险。 关于延期披露 2024 年年度报告及 2025 年第一季度报告的公告 证券代码：002198 证券简称：嘉应制药 公告编号：2025-017 广东嘉应制药股份有限公司 关于延期披露 2024 年年度报告及 2025 年第一季度报 告的公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 广东嘉应制药股份有限公司(以下简称"公司")原定于 2025 年 4 月 25 日披 露《2024 年年度报告》及《2025 年第一季度报告》。由于年度报告编辑及复核 工作量较大，预计无法按照原预 ...

本公司及董事会保证本公告内容的真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 广东嘉应制药股份有限公司（以下简称"公司"）原定于 2025 年 4 月 30 日披露 2025 年第一季度报告。现公司根据前述报告编制工作进展情况，经向深 圳证券交易所申请并获同意，公司 2025 年第一季度报告的披露时间变更为 2025 年 4 月 25 日。公司 2025 年第一季度报告于 2025 年 4 月 25 日在巨 潮资讯网、《证券时报》、《中国证券报》、《证券日报》上披露。敬请投资者 注意查阅。 特此公告。 广东嘉应制药股份有限公司董事会 2025年4月14日 关于提前披露 2025 年第一季度报告的提示性公告 证券代码：002198 证券简称：嘉应制药 公告编号：2025-016 广东嘉应制药股份有限公司 关于提前披露 2025 年第一季度报告的提示性公告 ...

嘉应制药（002198）公告，公司原定于2025年4月30日披露2025年第一季度报告。现经向深圳证券交易 所申请并获同意，披露时间变更为2025年4月25日。公司2025年第一季度报告将于2025年4月25日在巨潮 资讯网、《证券时报》、《中国证券报》、《证券日报》上披露。敬请投资者注意查阅。 ...